Home / Healthcare/ Breathe Free Lanka partners Novartis in Sri Lanka to provide Ultibro Breezhaler

Breathe Free Lanka partners Novartis in Sri Lanka to provide Ultibro Breezhaler


Comments / {{hitsCtrl.values.hits}} Views / Monday, 26 August 2019 01:09


  • Initiative to provide once-daily maintenance solution for COPD patients

 

Breathe Free Lanka Ltd., a subsidiary of Cipla Ltd. has announced a partnership with Novartis for the marketing and distribution of Novartis’ Ultibro Breezhaler. This partnership will enable Breathe Free Lanka to facilitate easy access to Ultibro Breezhaler for patients in Sri Lanka to help them alleviate specific debilitating symptoms of COPD. 

As part of this agreement, Novartis will be responsible for manufacturing Ultibro Breezhaler at its global facilities in line with its commitment to quality, effectiveness and safety.

This development is in line with Cipla’s aim of addressing unmet patient needs in respiratory and other therapy areas in Sri Lanka. The company has a strong record of focusing its efforts on improving healthcare and enhancing access to innovative medicines for improved disease management and better quality of life, especially for patients who currently do not have easy access to critical medicines. Cipla International Business (Europe and Emerging Markets) CEO Nishant Saxena said: “As market leaders with significant presence in the respiratory segment, we look forward to leveraging our marketing and distribution strengths in Sri Lanka to take this product to as many patients as possible in furtherance of our purpose of ‘Caring for Life’.”

Novartis Singapore and Asian Emerging Markets Managing Director Celine Landie said: “Our partnership with Cipla is aligned with the Novartis commitment to address the unmet medical needs of COPD patients and improving their quality of life by providing innovative medicines and devices.” 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Parliamentary debate on forensic audit reports: Only two constructive suggestions

Monday, 24 February 2020

A debate without substance I spent two afternoons last week in watching the live debate on the forensic audit reports by Sri Lanka’s Parliamentarians. Sadly, there were only two Parliamentarians who made constructive suggestions that should merit a


‘Stutiyi’, my dearest Sri Lankan friends

Monday, 24 February 2020

My heartstrings have been pulled every day during the past few weeks. When following closely my home-country’s all-out efforts to fight the COVID-19 epidemic, I’m always being touched by the most concrete solidarity and the most sincere friendshi


COVID-19 in China: Testing the quality of humanity

Monday, 24 February 2020

Many opinions have been penned across the world over the outbreak of the new strain of influenza. It has killed thousands of innocent Chinese according to official figures. As it came from China, no candlelight vigil has been held in major cities in


Extremes of two world economies – Communist and Capitalist

Monday, 24 February 2020

Up until now, two major economies have dominated the world – the communist economy, militarily controlled and with only state enterprises (or so it was believed outside of their military borders) and the so-called capitalist economy that commenced


Columnists More